SITE001-0165

SITE001 (USA) › SITE001-0165

SITE001-0165

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE001 (USA) · Dr. Reyes
consented 2026-03-17

completed

AEs

8

Serious

1

Dropout signal

–

Adverse events

8

Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-10-04 (study day 9); relationship: not assessed

moderate assessed

Grade 4 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-10-02 (study day 7); relationship: not assessed; serious criteria: life-threatening

severe serious assessed

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-10-02 (study day 7); relationship: not assessed

mild assessed

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-10-01 (study day 6); relationship: not assessed

moderate assessed

Grade 1 Constipation — outcome: RECOVERED/RESOLVED; onset 2022-09-29 (study day 4); relationship: RELATED

mild assessed

Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-09-29 (study day 4); relationship: NOT RELATED

moderate assessed

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-09-27 (study day 2); relationship: NOT RELATED

moderate assessed

Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-09-27 (study day 2); relationship: not assessed

mild assessed

Data queries

0

No data queries. Open queries would appear here for this patient.